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L ipodystrophies are acquired or in-herited disorders characterized byselective or generalized loss of adi-
pose tissue. Affected patients are predis-
posed to insulin resistance and metabolic
complications of insulin resistance (1).
Noticeably, patients with acquired or he-
reditary generalized forms are extremely
insulin resistant (2,3). On the other hand,
in partial forms the ample phenotypic
spectrum determines clinical presenta-
tions and metabolic profiles of variable
degrees (4). Among diagnostic resources
for fat distribution evaluation, dual-
energy X-ray absorptiometry (DEXA) has
been utilized because of its accuracy, re-
producibility, and good correlation with
computerized tomography (5,6). The
purpose of this study was to evaluate
body composition with DEXA in patients
with different types of lipodystrophy and
to determine the correlation between
densitometric, clinical, and metabolic
features.
RESEARCH DESIGN AND
METHODS— Five female patients
with lipodystrophy phenotype had been
studied, selected from an outpatient
clinic. Three patients had diabetes (pa-
tients 1, 4, and 5). Laboratory evaluation
was performed. Patients signed an in-
formed consent, and the ethical commit-
tee of the institution approved this study.
Whole-body DEXA scans were obtained
at DENSSO laboratory with GE Lunar
Prodigy Advance software, version 9.5,
LNR 41569 model.
RESULTS— The relevant results are
depicted in Table 1. Plasma leptin was
markedly diminished, consistent with
body fat mass. All patients exhibited se-
vere hepatic steatosis at ultrasound study.
Case reports
Patient 1. Patient 1 was a 42 year-old
woman who first noticed fat redistribu-
tion after her first pregnancy. She was di-
agnosed for hypertension and type 2
diabetes at 39 years of age and had isch-
emic heart disease recently recognized.
Physical examination revealed abnormal
fat distribution showing lack of adipose
tissue in members extending to the glu-
teus region and fat accumulation in the
abdomen, face, and neck. DNA sequenc-
ing showed the R482Qmutation in lamin
A/C gene (LMNA), leading to a diagnosis
of familial partial lipodystrophy of Dun-
nigan variety (FPLD). Two older sisters
(patients 2 and 3) with the same pheno-
type were invited and exhibited the same
mutation.
Patient 2. Patient 2 was 45-year-old
woman and was patient 1’s sister. She no-
ticed a lack of fat from extremities and
abdominal fat deposition since puberty.
Her appearance was similar to that of her
sister.
Patient 3. Patient 3 was a 47-year-old
woman, also patient 1’s sister, who first
noticed fat redistribution around pu-
berty. Results of her physical examination
were similar to those of her sisters, except
for hirsutism and weight.
Patient 4. Patient 4 was a 54-year-old
woman who had noticed fat redistribu-
tion and muscular arms since childhood.
She presented poorly controlled type 2
diabetes, hypertension, and dyslipidemia.
During physical examination, marked
lack of adipose tissue in face, arms, and
trunk and normal fat deposition in hip
and legs were noted. Extensive investiga-
tion was undertaken for autoimmunity,
and results were negative (except for thy-
roid antibodies). Clinical presentation
pointed to Barraquer-Simons syndrome.
Patient 5. Patient 5 was a 30-year-old
woman who presented congenital gener-
alized lipodystrophy, diagnosed at birth.
She started insulin therapy at 2 years of
age. She presented a good response to ro-
siglitazone therapy, reducing insulin dos-
age from 2.74 units  kg1  day1 to 1.5
units  kg1  day1 within 3 months.
However, the drug was withdrawn be-
cause of adverse effects. She exhibited a
complete absence of subcutaneous fat,
with fat preservation in palms, soles, and
scalp.
DEXA analysis of body composition
Remarkably, fat mass differs between par-
tial (patients 1–4) and generalized (pa-
tient 5) lipodystrophies. In the same way,
the ratio between the fat percentage in
trunk and inferior members, defined as
fat mass ratio (FMR) to characterize lipo-
dystrophies (7), wasmarkedly different in
partial lipodystrophies subtypes. Interest-
ingly, patients with fat accumulation in
the upper-body compartment demon-
strate an FMR 1.0, while a low FMR
(1.0) was present in patient 4, with
lower body fat accumulation. Patient 5,
with the generalized form, exhibited a
normal value (around 1.0) once she pre-
sented an extremely low fat percentage in
both compartments.
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CONCLUSIONS— The phenotypic
characterization of five patients with dif-
ferent forms of lipodystrophy was per-
formed, and body composition evaluated
by DEXA is presented. Patients 1, 2, and 3
were diagnosed with FPLD. LMNA se-
quencing showed an R482Qmutation. As
pointed out by Garg et al. (4), this type of
lipodystrophy can show some clinical
heterogeneity at presentation. This was
clearly demonstrated by DEXA; patient 3,
with lower total and troncular fat percent-
age, presented a less aggressive metabolic
profile. She had a greater BMI than her
diabetic sister but less fat mass and greater
lean mass. Accordingly, she presented
lower levels of plasma leptin, fasting insu-
lin, and homeostasis model assessment of
insulin resistance (1.26 3.09 compared
with patient 2, who was also nondia-
betic). This finding suggests that her body
composition has provided some meta-
bolic protection.
Patient 4 had a phenotype suggestive
of an acquired partial form (Barraquer-
Simons). In DEXA analyses, she was the
only one with a greater percentage of gy-
noid fat instead of android fat. This accu-
mulation of peripheral fat, however, did
not confer a less aggressivemetabolic pro-
file, as could be expected. Patients with
Barraquer-Simons syndrome usually
present gradual onset and cephalocaudal
progression for fat loss. They also exhibit
evidence for autoimmune disease (8,9)
but seldom present metabolic disarrange-
ment (10). This patient has some coinci-
dental findings for Barraquer-Simons, but
she presented a severe metabolic disar-
rangement. An alternative hypothesis is
that the case reported here is a hereditary
form with an unknown genetic basis. In-
deed, Misra et al. (11) studied nine cases
of acquired partial lipodystrophy with
techniques of molecular biology, in four
of whom were mutations in the LMNB2
gene. Clearly, further studies are neces-
sary to clarify the genetic basis of the
syndrome.
Only recently, DEXA has been used
for body composition estimation. There
are few studies describing its use in lipo-
dystrophic patients (12,13). To our
knowledge, most were performed in ac-
quired lipodystrophies, asHIV treatment–
related lipodystrophy. Bonnet et al. (7)
showed body composition reference val-
ues for fat distribution evaluation. In this
study, 162 HIV-infected men and 241
control subjects were evaluated, and FMR
was suggested as helpful for defining lip-
odystrophy diagnosis. Comparing the
group using antiretroviral therapy with
control subjects, they found a cutoff of
1.3  0.2 for distinction between them.
In the present study, the patients with
FPLD have FMRs well above this cutoff
point (2.38, 1.8, and 1.91, respectively,
for patients 1, 2, and 3). By contrast, pa-
Table 1—Laboratory tests/DEXA
Test Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Fasting glucose (70–100 mg/dl) 96 102 81 153 111
2-h glucose (140 mg/dl) — 108 122 — —
Insulin (6- 27 U/ml) 7.5 12.3 6.3 23.3 —
AlC (%) 7.1 6.1 6 10.9 7.2
Cholesterol (mg/dl)
Total (200) 202 244 224 158 179
LDL (130) 126 157 153 72 105
HDL (45) 35 39 40 35 31
Triglycerides (150 mg/dl) 204 125 154 253 217
AST (10–37 mg/dl) 44 28 15 20 21
ALT (10–37 mg/dl) 84 37 11 19 27
Uric acid (2.4–5.7 mg/dl) 4.2 3 3.7 4.4 6.2
Leptin (17 ng/ml) 7.1 7.3 2.7 5.6 0.2
Fibrinogen (180–350 mg/dl) 381 407 283.5 210.4 350.5
Lipoprotein (30 ng/dl) 46.5 39.8 21.13 11.5 19.3
RCP (mg/dl) 0.08 0.17 0.04 — —
ApoA (125–215 mg/dl) 135 145 117 88 110
ApoB (55–125 mg/dl) 110 121 126 57 103
DEXA
Height (cm) 164.00 165.00 161.00 166.00 165.00
Weight (kg) 60.91 61.40 60.40 73.62 59.10
BMI (kg/m²) 22.64 22.60 23.10 26.70 21.50
Fat (%)
Total 22.70 27.60 16.60 23.10 5.10
Trunk 30.90 34.40 21.40 23.40 5.40
Upper-body limbs 15.80 22.10 12.50 9.70 4.20
Lower-body limbs 13.00 19.10 11.20 27.70 4.40
Android 36.70 39.00 26.00 22.80 4.70
Gynoid 24.60 32.20 19.40 30.20 6.10
Fat mass (g) 13.39 16.33 9.68 16.43 2.86
Lean mass (g) 45.46 42.94 48.64 54.77 53.64
FMR 2.38 1.80 1.91 0.84 1.23
ALT, alanine aminotransferase; AST, aspartate aminotransferase; apo, apolipoprotein; RCP, reactive C protein.
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tient 4, with a partial lipodystrophy that
spares fat from lower extremities, had an
FMR of 0.84.
In conclusion, in this study DEXA
measurements of fat distribution helped
to better characterize diverse forms of li-
podystrophy. Utilization of FMR could be
helpful in precocious identification of
partial forms, where this ratio could be
or1.0. Further studies with larger series
are necessary to improve strategies in the
diagnosis of lipodystrophies.
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